Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Now Covered by LADENBURG THALM/SH SH

LADENBURG THALM/SH SH began coverage on shares of Calidi Biotherapeutics (NYSEAMERICAN:CLDI) in a research report sent to investors on Thursday, Benzinga reports. The firm issued a buy rating and a $1.00 price target on the stock.

Several other equities research analysts also recently weighed in on the company. HC Wainwright reduced their price target on Calidi Biotherapeutics from $11.00 to $2.00 and set a buy rating on the stock in a report on Thursday, March 21st. Robert W. Baird reduced their price target on Calidi Biotherapeutics from $4.50 to $2.00 and set an outperform rating on the stock in a report on Wednesday, May 15th.

Calidi Biotherapeutics Price Performance

NYSEAMERICAN:CLDI opened at $0.20 on Thursday. Calidi Biotherapeutics has a 12 month low of $0.14 and a 12 month high of $13.79.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.07.

Institutional Trading of Calidi Biotherapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in CLDI. Spectrum Asset Management Inc. NB CA purchased a new position in Calidi Biotherapeutics in the 1st quarter worth $94,000. Apollo Management Holdings L.P. purchased a new position in Calidi Biotherapeutics in the 1st quarter worth $71,000. Evermay Wealth Management LLC purchased a new position in Calidi Biotherapeutics in the 1st quarter worth $36,000. Finally, Magnetar Financial LLC purchased a new position in Calidi Biotherapeutics in the 1st quarter worth $36,000. Hedge funds and other institutional investors own 12.53% of the company’s stock.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.